The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23062919
Abstract: Multiple myeloma (MM) is characterized by remarkable cytogenetic/molecular heterogeneity among patients and intraclonal diversity even in a single patient. We previously demonstrated that PDPK1, the master kinase of series of AGC kinases, is universally active… read more here.
Keywords: rsk2 akt; rsk2; multiple myeloma; dual targeting ... See more keywords